Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D).

Objective: To evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with type II diabetes (T2D).

Methods: This multicenter, retrospective study collected real-world data from various public & private hospitals, and primary care clinics in Pakistan. The total duration of clinical data collection was six months (April and September 2022) from 183 diabetic patients across different centers in Pakistan. Patients who had received IDegLira in combination with basal/premixed insulin, OHAs, or both regimes (basal/premixed insulin and OHAs) for the treatment of Type-II diabetes (T2D) in the Pakistani population were analyzed.

Results: After receiving IDegLira therapy for six months, mean HbA1c was reduced by -1.1%, mean body weight reduced by 1.2 kg, fasting blood glucose levels (mg/dl): 164.7 (±36.2) to 134.4 (±32.9)] and random blood sugar (mg/dl): 240.1 (±71.4) to 207.6 (±77.8)]. The mean IDegLira dose steps were 19.9 (±6.7) at initiation and 23.5 (±7.9) at follow-up. Overall, adverse events reported were generally related to gastrointestinal, and few were related to headache, fatigue, and hypoglycemia events.

Conclusion: The values of HbA1c and body weight decreased for the patients after using iDeglira for six months. Therefore, the medicine had a positive impact on the outcome of the study.